Tempus AI experienced a notable downturn as profit-taking swept through the shares following a major multi-day rally. The weakness unfolded despite positive regulatory momentum, as the company announced FDA 510(k) clearance for its artificial intelligence software designed to detect indicators of pulmonary hypertension from standard electrocardiograms. While this clearance represents a key expansion of the company’s diagnostic AI portfolio, the market reaction exemplified a classic sell-the-news response. Capitalizing on the positive announcement, market participants locked in substantial gains accumulated during the stock’s recent steep advance, which had been driven by optimism surrounding its planned acquisition of Personalis and…